Table 2.
Relationships Between Multiple Proteins at Age 70 Years and Incident CVD in ULSAM
| Variable | Gene name | Age‐adjusted | Adjusted for traditional cardiovascular risk factors | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI lower | 95%CI higher | P value | HR | 95%CI lower | 95%CI higher | P value | ||
| N‐terminal prohormone brain natriuretic peptide | NTproBNP | 1.53 | 1.33 | 1.75 | 6.22E‐10 | 1.54 | 1.34 | 1.78 | 3.00E‐09 |
| Growth differentiation factor 15 | GDF15 | 1.44 | 1.27 | 1.63 | 1.27E‐08 | 1.31 | 1.15 | 1.49 | 5.05E‐05 |
| WAP 4‐disulfide core domain protein 2 | WFDC2 | 1.41 | 1.24 | 1.59 | 1.15E‐07 | 1.36 | 1.19 | 1.56 | 7.64E‐06 |
| Macrophage metalloelastase | MMP12 | 1.36 | 1.2 | 1.54 | 9.06E‐07 | 1.24 | 1.08 | 1.41 | 1.76E‐03 |
| Hepatitis A virus cellular receptor 1 | KIM1 | 1.34 | 1.18 | 1.52 | 5.34E‐06 | 1.2 | 1.05 | 1.37 | 7.26E‐03 |
| Tumor necrosis factor receptor superfamily member 10B | TRAILR2 | 1.32 | 1.17 | 1.49 | 1.08E‐05 | 1.26 | 1.1 | 1.43 | 5.24E‐04 |
| CCN family member 4 | WISP1 | 1.28 | 1.13 | 1.44 | 5.36E‐05 | 1.18 | 1.04 | 1.34 | 9.55E‐03 |
| Thrombospondin‐2 | THBS2 | 1.28 | 1.14 | 1.45 | 5.81E‐05 | 1.18 | 1.03 | 1.34 | 1.60E‐02 |
| Trefoil factor 3 | TFF3 | 1.27 | 1.13 | 1.44 | 1.18E‐04 | 1.26 | 1.11 | 1.44 | 3.55E‐04 |
| Interleukin 1 receptor antagonist protein | IL1ra | 1.25 | 1.12 | 1.41 | 1.47E‐04 | 1.18 | 1.03 | 1.36 | 1.69E‐02 |
| Fatty acid‐binding protein, adipocyte | FABP4 | 1.26 | 1.12 | 1.42 | 1.51E‐04 | 1.21 | 1.05 | 1.39 | 8.09E‐03 |
| Interleukin 6 | IL6 | 1.24 | 1.1 | 1.39 | 3.27E‐04 | 1.15 | 1.01 | 1.31 | 3.97E‐02 |
| Metalloproteinase inhibitor 1 | TIMP1 | 1.24 | 1.1 | 1.4 | 3.46E‐04 | 1.14 | 1.01 | 1.29 | 3.93E‐02 |
| Galectin‐9 | Gal9 | 1.24 | 1.1 | 1.39 | 4.38E‐04 | 1.16 | 1.02 | 1.33 | 2.34E‐02 |
| Tumor necrosis factor receptor superfamily member 19 | TNFRSF19 | 1.24 | 1.1 | 1.41 | 4.98E‐04 | 1.28 | 1.12 | 1.46 | 2.25E‐04 |
| Keratin, type I cytoskeletal 19 | KRT19 | 1.24 | 1.1 | 1.39 | 5.43E‐04 | 1.17 | 1.03 | 1.33 | 1.64E‐02 |
| Urokinase plasminogen activator surface receptor | UPAR | 1.23 | 1.09 | 1.38 | 5.92E‐04 | 1.15 | 1.02 | 1.31 | 2.65E‐02 |
| Transmembrane glycoprotein NMB | GPNMB | 1.22 | 1.09 | 1.38 | 6.78E‐04 | 1.21 | 1.07 | 1.37 | 1.86E‐03 |
| V‐set and immunoglobulin domain‐containing protein 4 | VSIG4 | 1.23 | 1.09 | 1.39 | 8.19E‐04 | 1.22 | 1.07 | 1.38 | 2.74E‐03 |
| Corticotropin‐releasing factor‐binding protein | CRHBP | 1.23 | 1.09 | 1.38 | 8.26E‐04 | 1.15 | 1.02 | 1.31 | 2.66E‐02 |
| Transferrin receptor protein 1 | TR | 1.23 | 1.09 | 1.39 | 8.39E‐04 | 1.23 | 1.08 | 1.4 | 1.70E‐03 |
| Uromodulin | UMOD | 0.82 | 0.73 | 0.92 | 9.60E‐04 | 0.86 | 0.76 | 0.97 | 1.43E‐02 |
| Protein S100‐A12 | ENRAGE | 1.22 | 1.08 | 1.37 | 1.26E‐03 | 1.15 | 1.01 | 1.31 | 4.13E‐02 |
| Macrophage receptor MARCO | MARCO | 1.22 | 1.08 | 1.37 | 1.33E‐03 | 1.2 | 1.06 | 1.36 | 3.34E‐03 |
| Tumor necrosis factor receptor superfamily member 19L | RELT | 1.23 | 1.08 | 1.39 | 1.35E‐03 | 1.18 | 1.03 | 1.34 | 1.38E‐02 |
| Amphiregulin | AREG | 1.22 | 1.08 | 1.38 | 1.36E‐03 | 1.19 | 1.05 | 1.35 | 7.81E‐03 |
| Tumor necrosis factor ligand superfamily member 12 | TWEAK | 0.83 | 0.74 | 0.93 | 1.84E‐03 | 0.87 | 0.77 | 0.98 | 2.62E‐02 |
| Metalloproteinase inhibitor 4 | TIMP4 | 1.21 | 1.07 | 1.37 | 1.96E‐03 | 1.23 | 1.08 | 1.4 | 1.57E‐03 |
| Inactive tyrosine‐protein kinase 7 | PTK7 | 1.21 | 1.07 | 1.37 | 1.96E‐03 | 1.19 | 1.05 | 1.35 | 5.11E‐03 |
| Follistatin‐related protein 3 | FSTL3 | 1.22 | 1.07 | 1.38 | 2.05E‐03 | 1.17 | 1.03 | 1.33 | 1.45E‐02 |
| Tissue factor pathway inhibitor 2 | TFPI2 | 1.21 | 1.07 | 1.36 | 2.26E‐03 | 1.18 | 1.04 | 1.34 | 1.12E‐02 |
| Leukocyte immunoglobulin‐like receptor subfamily B member 4 | LILRB4 | 1.21 | 1.07 | 1.36 | 2.72E‐03 | 1.19 | 1.05 | 1.35 | 6.50E‐03 |
| Collectin‐12 | COLEC12 | 1.21 | 1.07 | 1.36 | 2.76E‐03 | 1.21 | 1.07 | 1.38 | 2.52E‐03 |
| Insulin‐like growth factor‐binding protein 7 | IGFBP7 | 1.21 | 1.07 | 1.37 | 2.80E‐03 | 1.14 | 1 | 1.29 | 4.86E‐02 |
| Tumor necrosis factor receptor superfamily member 10A | TNFRSF10A | 1.2 | 1.06 | 1.35 | 3.37E‐03 | 1.14 | 1.01 | 1.29 | 3.73E‐02 |
| Triggering receptor expressed on myeloid cells 1 | TREM1 | 1.2 | 1.06 | 1.35 | 3.45E‐03 | 1.18 | 1.04 | 1.34 | 1.13E‐02 |
| Carcinoembryonic antigen‐related cell adhesion molecule 5 | CEACAM5 | 1.2 | 1.06 | 1.35 | 3.59E‐03 | 1.17 | 1.03 | 1.34 | 1.72E‐02 |
| Leukocyte‐associated immunoglobulin‐like receptor 1 | LAIR1 | 1.19 | 1.06 | 1.35 | 4.11E‐03 | 1.16 | 1.03 | 1.32 | 1.85E‐02 |
Only proteins with a false discovery rate <0.05 for age‐adjusted P value and multiadjusted P value <0.05 are shown (n=38). CVD indicates cardiovascular disease; HR, hazard ratio; MARCO, macrophage receptor with collagenous structure; and ULSAM, Uppsala Longitudinal Study of Adult Men.